JPRN-UMIN000001233CompletedPhase 2
Phase II clinical trial of the first-line Stop-and-Go modified FOLFOX6 and bevacizmab for patients with unresectable/recurrent colorectal cancer - Phase II clinical trial of the first-line Stop-and-Go modified FOLFOX6 and bevacizmab for patients with unresectable/recurrent colorectal cancer
Mlnlstry of health, Labour and Welfare0 sites50 target enrollmentStarted: July 7, 2008Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)active other malignancies 2)history of the severe drug hypersensitivity 3)clinically significant infectious disease(body temperature less than 38.0 degrees) 4)severe complications (ileus, bowel obstruction, interstitial lung disease, pulmonary fibrosis, uncontrolled diabetes mellitus, heart failure, renal failure, hepatic failure and so on) 5)uncontrollable hypertension 6)urinary protein (more than 1+) 7)Patients who have abnormal findings on ECG and need any treatment (within 2 weeks before the registration.) 8)Moderate/severe pleural effusion or ascites 9)Symptomatic brain metastasis 10)Any significant bleedings 11)Evidence of bleeding diathesis 12)History of thoromboembolitic disease 13)Uncontrolled watery diarrhea. Watery colostomy output without trouble with patient's daily living is allowed. 14)Surgical procedure within 4 weeks before registration (the implanted central venous port is allowed.) 15)Patient who underwents the implantation of the central venous port within a day prior to start of study drugs. 16)Pregnant or lactating women, women who are capable of pregnancy or intend to get pregnant, men who don't intend to have protected intercourse. 17)Any other cases who are regarded as Inadequate for study enrollment by the attending doctors.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase II clinical trial of palliativ treatment of patients with advanced non-operable gastric carcinoma: FLOT regimen followed by AIO regimen and irinotecan combined with artificial nutrition and physical activity - impact on quality of life and fatigue: FLOTIRI gastric cancer trialAdvanced non-resectable adenocarcinoma of the stomach and the gastro-oesophageal junctionMedDRA version: 15.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014895-23-DEniversitätsklinikum Erlangen50
Completed
Phase 2
Phase 2 trial of first-line combination therapy of cisplatin, pemetrexed and nivolumab in participants with unresectable malignant pleural mesotheliomamalignant pleural mesotheliomaJPRN-UMIN000030892Okayama Rosai Hospital18
Active, not recruiting
Phase 1
ABORL - A Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB in patients with locally advanced/metastatic head and neck cancer harboring an homozygous deletion of CDKN2A, and/or an amplification of CCND1 and/or of CDK6 refractory to standards treatmentsPatients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-EGFR-basedMedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004537-25-FRCentre Léon Bérard25
Completed
Phase 2
An early phase II trial for efficacy and safety of TTA-121 on autism spectrum disorderAutism spectrum disorderJPRN-UMIN000031412Hamamatsu University School of Medicine, Department of Psychiatry144
Active, not recruiting
Phase 1
Study of the efficacy and safety of the Bintrafusp alfa (M7824) in previously treated cancer called malignant pleural mesothelioma.EUCTR2020-004902-67-ESFundación GECP47